Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

82.84EUR
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
€82.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
641,210
52-wk High
€112.65
52-wk Low
€74.54

Select another date:

Thu, May 17 2018

Photo

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find a drug-industry partner to share further development costs for one of them.

UPDATE 2-Merck KGaA's lung cancer drugs show promise in early-stage trials

* Shares up 5.2 pct (Adds Merck ruling out enlisting partner for tepotinib development)

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT, May 16 Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping the company's efforts to find drug-industry partners to share further development costs.

UPDATE 1-Merck KGaA Q1 earnings down on liquid crystals, currencies

* Strong euro to cause 5-7 percent drag on 2018 EBITDA (Adds detailed guidance, forex effects)

Merck KGaA Q1 earnings down on liquid crystals, currencies

FRANKFURT, May 15 Germany's Merck KGaA saw earnings decline in the first quarter, hurt by Chinese competition in liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

Merck KGaA family says unreservedly behind the pharma unit

DARMSTADT, Germany The family behind Germany's Merck KGaA said it was fully committed to the diversified group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales.

UPDATE 1-Merck KGaA family says unreservedly behind the pharma unit

* Family backs pharma unit even if avelumab not a blockbuster

Merck KGaA family says unreservedly behind the pharma unit

DARMSTADT, Germany, May 3 The family behind Germany's Merck KGaA said it was fully committed to the group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales.

BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals

* MERCK KGAA, DARMSTADT, GERMANY TO DEVELOP ABITUZUMAB IN METASTATIC COLORECTAL CANCER WITH SFJ PHARMACEUTICALS GROUP

BRIEF-Merck KGaA Receives Patent For CRISPR Technology In China

* MERCK RECEIVES PATENT FOR CRISPR TECHNOLOGY IN CHINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: